Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC)No ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results